| Drug Name |
Alendronic acid |
| Drug ID |
BADD_D00066 |
| Description |
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959]. |
| Indications and Usage |
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label]. |
| Marketing Status |
approved |
| ATC Code |
M05BA04 |
| DrugBank ID |
DB00630
|
| KEGG ID |
D07119
|
| MeSH ID |
D019386
|
| PubChem ID |
2088
|
| TTD Drug ID |
D09KLR
|
| NDC Product Code |
Not Available |
| UNII |
X1J18R4W8P
|
| Synonyms |
Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax |
